{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:57:34Z","timestamp":1740135454114,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individuals with schizophrenia are a vulnerable and under-served population who are also at risk for severe morbidity and mortality following COVID-19 infection. Our research was designed to identify factors that put individuals with schizophrenia at increased risk of COVID-19 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a retrospective cohort analysis of medical and pharmacy claims among 493,796 individuals residing in the United States with schizophrenia or schizoaffective disorder, between January 1, 2019 and June 30, 2020. A confirmed diagnosis of COVID-19 infection by September 30, 2020 was regressed on demographics, social determinants, comorbidity, and pre-pandemic (December 2019 \u2013 February 2020) healthcare utilization characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 35,249 (7.1%) individuals were diagnosed with COVID-19. Elevated odds of COVID-19 infection were associated with age, increasing consistently from 40-49 years (OR: 1.16) to 80+ years (OR:5.92), male sex (OR: 1.08), Medicaid (OR: 2.17) or Medicare (OR: 1.23) insurance, African American race (OR: 1.42), Hispanic ethnicity (OR: 1.23), and higher Charlson Comorbidity Index. Select psychiatric comorbidities (depressive disorder, adjustment disorder, bipolar disorder, anxiety, and sleep-wake disorder) were associated with elevated odds of infection, while alcohol use disorder and PTSD were associated with lower odds. A pre-pandemic psychiatry (OR:0.56) or community mental health center (OR:0.55) visit were associated with lower odds as was antipsychotic treatment with long-acting injectable antipsychotic (OR: 0.72) and oral antipsychotic (OR: 0.62).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among individuals with schizophrenia, risk of COVID-19 infection was substantially higher among those with fewer economic resources, with greater medical and psychiatric comorbidity burden, and those who resided in African American or Hispanic communities. In contrast, individuals actively engaged in psychiatric treatment had substantially lower likelihood of infection. These results provide insights for healthcare providers that can translate into improved identification of at-risk individuals and interventions to reduce the risk and consequences of COVID-19 infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04026-7","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:06:15Z","timestamp":1654182375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States"],"prefix":"10.1186","volume":"22","author":[{"given":"Joshua N.","family":"Liberman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Pesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Pat","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Ruetsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"4026_CR1","doi-asserted-by":"publisher","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016 Jul 2;388(10039):86-97. doi: https:\/\/doi.org\/10.1016\/S0140-6736(15)01121-6. Epub 2016 Jan 15. PMID: 26777917; PMCID: PMC4940219.","DOI":"10.1016\/S0140-6736(15)01121-6"},{"issue":"4","key":"4026_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/schbul\/sbaa051","volume":"46","author":"N Kozloff","year":"2020","unstructured":"Kozloff N, Mulsant B, Stergiopoulos V, Voinekos A. The COVID-19 Global Pandemic: Implications for People with Schizophrenia and Related Disorders. Schizophrenia Bulletin. 2020;46(4):752\u20137. https:\/\/doi.org\/10.1093\/schbul\/sbaa051.","journal-title":"Schizophrenia Bulletin"},{"issue":"1\u20133","key":"4026_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","volume":"86","author":"HA Nasrallah","year":"2006","unstructured":"Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATI schizophrenia trial sample at baseline. Schizophrenia Res. 2006;86(1\u20133):15\u201322.","journal-title":"Schizophrenia Res"},{"key":"4026_CR4","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S2666-7568*20)30013-1","volume":"1","author":"H Yang","year":"2020","unstructured":"Yang H, Chen W, Hu W, et al. Pre-pandemic psychiatric disorders and risk COVID-19: a UK Biobank cohort analysis. Lancet Healthy Longev. 2020;1:e69-79. https:\/\/doi.org\/10.1016\/S2666-7568*20)30013-1.","journal-title":"Lancet Healthy Longev"},{"key":"4026_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews. 2008;30:67\u201376. https:\/\/doi.org\/10.1093\/epirev\/mxn001 epub 2008 May 14 PMID: 18480098.","journal-title":"Epidemiologic Reviews"},{"issue":"5","key":"4026_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/schbul\/sbab012","volume":"47","author":"DT Bitan","year":"2021","unstructured":"Bitan DT, Krieger I, Kridin K, et al. COVID-19 prevalence and mortality among schizophrenia patients: A large-scale retrospective cohort study. Schizophrenia Bulletin. 2021;47(5):1211\u20137. https:\/\/doi.org\/10.1093\/schbul\/sbab012 Epub ahead of print.","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"4026_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2020.4442","volume":"78","author":"K Nemani","year":"2021","unstructured":"Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, Petkova E, Goff DC. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380\u20136.","journal-title":"JAMA Psychiatry"},{"key":"4026_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/wps.20806","volume":"20","author":"Q Wang","year":"2021","unstructured":"Wang Q, Xu R, Vokow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20:124\u201330.","journal-title":"World Psychiatry"},{"key":"4026_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12939-020-01242-z","volume":"19","author":"Y Rozenfeld","year":"2020","unstructured":"Rozenfeld Y, Beam J, Maier H, Haggerson W, Boudreau K, Carlson J, Medows R. A model of disparities: risk factors associated with COVID-19 infection. Int J Equity Health. 2020;19:126.","journal-title":"Int J Equity Health"},{"issue":"1","key":"4026_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1080\/22221751.2020.1787799","volume":"9","author":"T Liu","year":"2020","unstructured":"Liu T, Liang W, Zhong H, He J, Chen Z, He G, Song T, Chen S, Wang P, Li J, Lan Y, Cheng M, Huang J, Niu J, Xia L, Xiao J, Hu J, Lin L, Huang Q, Rong Z, Deng A, Zeng W, Li J, Li X, Tan X, Kang M, Guo L, Zhu Z, Gong D, Chen G, Dong M, Ma W. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. Emerg Microbes Infect. 2020;9(1):1546\u201353. https:\/\/doi.org\/10.1080\/22221751.2020.1787799.","journal-title":"Emerg Microbes Infect"},{"key":"4026_CR11","doi-asserted-by":"publisher","unstructured":"Lan F-Y, Filler R, Mathew S, Buley J, Eiliaki E, Bruno-Murtha LA, Osgood R, Christophi CA, Fernandez-Montero A, Kales SN. Sociodemographic risk factors for coronavirus disease 2019 (COVID-19) infection among Massachusetts healthcare workers: A retrospective cohort study. Infect Control Hosp Epidemiolhttps:\/\/doi.org\/10.1017\/ice.2021.17","DOI":"10.1017\/ice.2021.17"},{"issue":"10","key":"4026_CR12","doi-asserted-by":"publisher","first-page":"e2026010","DOI":"10.1001\/jamanetworkopen.2020.26010","volume":"3","author":"S Padalabalanarayanan","year":"2020","unstructured":"Padalabalanarayanan S, Hanumanthu VS, Sen B. Association of state stay-at-home orders and state-level African American population with COVID-19 case rates. JAMA Network Open. 2020;3(10):e2026010. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.26010.","journal-title":"JAMA Network Open"},{"key":"4026_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2021.02.002","volume":"229","author":"M Canal-Rivero","year":"2021","unstructured":"Canal-Rivero M, Catalan-Barragan R, Rubio-Garcia A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M, IBIS Translational Psychiatry Group. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population. Schizophrenia Research. 2021;229:53\u20134. https:\/\/doi.org\/10.1016\/j.schres.2021.02.002.","journal-title":"Schizophrenia Research"},{"key":"4026_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1192\/bjp.2020.151","volume":"219","author":"R Govind","year":"2021","unstructured":"Govind R, Fonseca de Freitas D, Pritchard M, Hayes RD, MacCabe JH. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psych. 2021;219:368\u201374. https:\/\/doi.org\/10.1192\/bjp.2020.151.","journal-title":"Br J Psych"},{"issue":"5","key":"4026_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Develop and validation. J Chron Dis. 1987;40(5):373\u201383.","journal-title":"J Chron Dis"},{"key":"4026_CR16","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.3346\/jkms.2020.35.3237","volume":"35","author":"W Ji","year":"2020","unstructured":"Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, Na Y, Choi H, Gong SY, Choi Y-H, Ko K-P, Im J-S, Jung J. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. Journal of Korean Medical Science. 2020;35:e237. https:\/\/doi.org\/10.3346\/jkms.2020.35.3237.","journal-title":"Journal of Korean Medical Science"},{"issue":"2","key":"4026_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","volume":"8","author":"M Taquet","year":"2021","unstructured":"Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62,354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130\u201340.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"4026_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1377\/hlthaff.2020.00598","volume":"39","author":"KMJ Azar","year":"2020","unstructured":"Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, Brown S, Pressman AR. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Affairs. 2020;39(7):1253\u201362. https:\/\/doi.org\/10.1377\/hlthaff.2020.00598.","journal-title":"Health Affairs"},{"issue":"1","key":"4026_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.amepre.2020.04.003","volume":"59","author":"MA Raifman","year":"2020","unstructured":"Raifman MA, Raifman JR. Disparities in the population at risk of severe illness from COVID-19 by race\/ethnicity and income. Am J Prevent Med. 2020;59(1):137\u20139.","journal-title":"Am J Prevent Med"},{"key":"4026_CR20","doi-asserted-by":"publisher","first-page":"620612","DOI":"10.3389\/fpsyt.2020.620612","volume":"11","author":"K Yazdi","year":"2020","unstructured":"Yazdi K, Fuchs-Leitner I, Rosenleitner J, Gerstgrasser NW. Impact of the COVID-19 Pandemic on Patients With Alcohol Use Disorder and Associated Risk Factors for Relapse. Front Psychiatry. 2020;11:620612.","journal-title":"Front Psychiatry"},{"key":"4026_CR21","doi-asserted-by":"publisher","first-page":"113552","DOI":"10.1016\/j.psychres.2020.113552","volume":"295","author":"CH Liu","year":"2021","unstructured":"Liu CH, Erdei C, Mittal L. Risk factors for depression, anxiety and PTSD symptoms in perinatal women during the COVID-19 pandemic. Psychiatry Research. 2021;295:113552.","journal-title":"Psychiatry Research"},{"key":"4026_CR22","doi-asserted-by":"publisher","first-page":"113172","DOI":"10.1016\/j.psychres.2020.113172","volume":"290","author":"CH Liu","year":"2020","unstructured":"Liu CH, Zhang E, Wong GTF, et al. Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: Clinical implications for US young adult mental health. Psychiatry Research. 2020;290:113172.","journal-title":"Psychiatry Research"},{"key":"4026_CR23","doi-asserted-by":"publisher","first-page":"113312","DOI":"10.1016\/j.psychres.2020.113312","volume":"292","author":"C Carmassi","year":"2020","unstructured":"Carmassi C, Gohi C, Dell\u2019Oste V, et al. PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID-19 pandemic. Psychiatry Research. 2020;292:113312.","journal-title":"Psychiatry Research"},{"key":"4026_CR24","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.eclinm.2021.101111","volume":"40","author":"L Liu","year":"2021","unstructured":"Liu L, Ni S-Y, Yan W, et al. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality. EClinicalMedicine. 2021;40:101111.","journal-title":"EClinicalMedicine"},{"key":"4026_CR25","doi-asserted-by":"publisher","unstructured":"Haderlein TP, Wong MS, Yua A, Llorente MD, Washington DL (2020). Association of PTSD with COVID-19 testing and infection in the Veterans Health Administration. J Psychiatr Res 2020;S0022-3956(20)31092-X. doi: https:\/\/doi.org\/10.1016\/j.jpsychires.2020.11.033","DOI":"10.1016\/j.jpsychires.2020.11.033"},{"issue":"9","key":"4026_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamapsychiatry.2020.1701","volume":"77","author":"KG Kahl","year":"2020","unstructured":"Kahl KG, Correll CU. Management of patients with severe mental illness during the coronavirus disease 2019 pandemic. JAMA Psychiatry Sept. 2020;77(9):977\u20138.","journal-title":"JAMA Psychiatry Sept."},{"key":"4026_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.genhosppsych.2021.05.005","volume":"71","author":"H Tendilla-Beltran","year":"2021","unstructured":"Tendilla-Beltran H, Flores G. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19. General Hospital Psychiatry. 2021;71:137\u20139. https:\/\/doi.org\/10.1016\/j.genhosppsych.2021.05.005.","journal-title":"General Hospital Psychiatry"},{"key":"4026_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.646701","author":"B Crespo-Facorro","year":"2021","unstructured":"Crespo-Facorro B, Ruiz-Veguilla M, Vazques-Bourgon J, et al. Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis. Frontiers in Pharmacology. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.646701.","journal-title":"Frontiers in Pharmacology"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04026-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:08:14Z","timestamp":1654182494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4026"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04026-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"type":"electronic","value":"1471-244X"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol including use of the Clarivate claims dataset was submitted to the Advarra Institutional Review Board (IRB), which approved the protocol and issued a waiver of consent. All data were de-identified and HIPAA compliant, and all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. Pesa and Petrillo are employees of Janssen Scientific Affairs. Drs. Liberman and Ruetsch are employees of Health Analytics, LLC which was funded to conduct the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}